Overview

Biweekly Intraperitoneal Oxaliplatin With Systemic Capecitabine and Bevacizumab for Patients With Peritoneal Carcinomatosis From Appendiceal or Colorectal Cancer

Status:
Active, not recruiting

Trial end date:
2024-05-31

Target enrollment:

Participant gender:

Summary

This study is to test escalating doses of intraperitoneal (IP) oxaliplatin in conjunction with systemic bevacizumab and capecitabine in patients with Peritoneal Carcinomatosis (PC) from either appendiceal or colorectal adenocarcinoma that have been adequately cytoreduced and have undergone a peritoneal scan demonstrating patency of at least one of the intraperitoneal ports that were placed at the time of debulking.

Phase:

Phase 1

Details

Lead Sponsor:

Washington University School of Medicine

Treatments:

Bevacizumab
Capecitabine
Oxaliplatin